HF
ZBIO icon

HRT Financial’s Zenas BioPharma ZBIO Stock Holding History

HRT Financial’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
8,879
-16,870
-66% -$335K ﹤0.01% 3333
2026
Q1 		$503K Buy
+25,749
New +$578K ﹤0.01% 2526
2024
Q4 		– Sell
-15,463
Closed -$261K – 3424
2024
Q3 		$261K Buy
+15,463
New +$278K ﹤0.01% 1866

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

HRT Financial's ZBIO Position: Q2 2026 in Review

HRT Financial reduced its Zenas BioPharma (ZBIO) stake by 66% in Q2 2026, selling an estimated $335K and leaving 8,879 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #3333.

HRT Financial first reported a position in ZBIO in Q3 2024 and has held it in 3 quarters since. The position peaked at $503K in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • HRT Financial held 8,879 shares of Zenas BioPharma worth $225K as of Q2 2026.
  • HRT Financial sold 16,870 Zenas BioPharma shares in Q2 2026, an estimated $335K.
  • Zenas BioPharma made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3333 holding.
  • HRT Financial first reported a position in Zenas BioPharma in Q3 2024 and has held it in 3 quarters since.
  • HRT Financial's Zenas BioPharma position peaked at $503K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.